Business
AVEO Oncology, an LG Chem company, Announces Two Poster Presentations at ASCO 2026 Annual Meeting
AVEO Oncology, an LG Chem company ("AVEO"), announced today that two abstracts were accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) 2026 annual meeting this May 29-June 2, 2026, in Chicago, IL.
About this update from Lg Chem Ltd.
[{"type":"text","content":"BOSTON, May 5, 2026 /PRNewswire/ -- AVEO Oncology, an LG Chem company ("AVEO"), announced today that two abstracts were accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) 2026 annual meeting this May 29-June 2, 2026, in Chicago, IL.","length":278,"tagName":"p"},{"type":"text","content":"Presentation Details","length":20,"tagName":"p"},{"type":"text","content":"Title: Final analysis of the TiNivo-2 phase 3 trial: Long-term outcome of tivozanib (Tivo) in patients with metastatic renal cell carcinoma (mRCC)First Author: Robert Motzer, MD, Memorial Sloan Kettering Cancer CenterAbstract Number: 4555Poster Session: Genitourinary Cancer—Kidney and BladderPoster Board: 34Date and Time: Sunday, May 31, 2026, 9:00am – 12:00 PM CDT","length":372,"tagName":"p"},{"type":"text","content":"Title: FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET mAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV negative head and neck squamous cell carcinoma (HNSCC)First Author: Julie E. Bauman, MD, MPH, George Washington University Cancer CenterAbstract Number: TPS6132Poster Session: Head and Neck CancerPoster Board: 585bDate and Time: Saturday, May 30, 2026, 1:30 PM – 4:30 PM CDT","length":488,"tagName":"p"},{"type":"text","content":"About AVEO Pharmaceuticals, Inc.AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet need, including ficlatuzumab in HPV-negative refractory head and neck squamous cell carcinoma and rilogrotug (also known as AV-380) in cancer cachexia. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name.","length":885,"tagName":"p"},{"type":"text","content":"About LG Chem, Ltd. and LG Chem Life SciencesLG Chem i...